Total Ankle Replacement in Hemophilia

(E-pub Ahead of Print)

Author(s): E. Carlos Rodriguez-Merchan*.

Journal Name: Cardiovascular & Hematological Disorders-Drug Targets
(Formerly Current Drug Targets - Cardiovascular & Hematological Disorders)

Become EABM
Become Reviewer


Introduction: Severe Ankle Hemophilic Arthropathy Can Be A Calamitous Sign Of Severe Hemophilia With Important Inferences For Activities Of Daily Living.

Aim: To Summarize The Contemporary Accessible Information On Total Ankle Replacement (Tar) For Ankle Hemophilic Arthropathy.

Methods: A Search Of Cochrane Library And Pubmed (Medline) Regarding The Role Of Tar In Ankle Hemophilic Arthropathy.

Results: The Insufficient Information Regarding Results Of Tar For Hemophilic Arthropathy Are Confined To Scanty Case Series And Case Reports. An Evaluation Of The Accessible Literature Reveals Encouraging But Inconstant Outcomes. The Reported Rate Of Adverse Events Is 33%. The Reported Anticipated Survival Of Tar Is 94% At 5 Years, 85% At 10 Years And 70% At 15 Years.

Conclusion: Whereas People With Advanced Hemophilic Arthropathy Of The Ankle Are Prone To Ameliorate Pain And Range Of Motion Following Tar, There Is Deficient Knowledge To Regularly Recommend Its Use. Adverse Events And Infection Percentages Are Disturbing. Moreover, The Lack Of Survival Analysis Knowledge Makes It Difficult To Assess The Benefit To People With Hemophilia. Tar Is A Demanding Surgical Procedure And Its Survival Is Not Comparable To That After Hip Or Knee Arthroplasty.

Keywords: Hemophilia, Hemophilic Arthropathy, Ankle, Total Ankle Replacement

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1871529X19666191210110626

Article Metrics

PDF: 7